acth-(4-7)--pro-gly-pro- and Stroke

Efficiency of Semax (synthetic derivative of ACTH-4-10) was studied in 30 patients in acute period of hemispherical ischemic stroke. Control group consisted of 80 patients with the strokes analogous in severity and location of the damages and which were treated by conventional therapy. Different clinical rating scales were used for both objectivization of the severity of the patients' state and estimation of the degree of neurological defect. The control of Semax influence on the functional state of the brain included monitoring of EEG with mapping, repeated analysis of somatosensory evoked potentials and their mapping. It was established that including of Semax in combined intensive therapy of acute ischemic stroke had some influence on the rate of restoration of the damaged neurological functions in terms of increasing the regress of general cerebral and focal, especially motor disorders. The most effective daily doses were 12 mg for patients with strokes of moderate severity and 18 mg for patients with severe strokes (treatment course--5 and 10 days).

Topics: Acute Disease; Adrenocorticotropic Hormone; Aged; Amino Acids; Brain Mapping; Electroencephalography; Evoked Potentials, Somatosensory; Female; Gangliosides; Humans; Male; Neuroprotective Agents; Nootropic Agents; Peptide Fragments; Severity of Illness Index; Stroke; Time Factors

One hundred and eighty-seven patients with different stages of cerebrovascular insufficiency (CI) have been examined. A diagnosis of CI was based on the results of neurological and neuropsychological study, ultrasonic dopplerography, rheo- and encephalography, electrocardiography, brain MRI and eyegrounds examination. Neurological scales were used for neurological status assessment and further data processing. The study aimed at evaluation of tolerability and clinical efficacy of the medication and complications in CI course. Semax treatment resulted in significant clinical improvement, stabilization of the disease progress and reduced a risk of stroke and transitory ischemic attacks in the disease course. The drug is featured by minor percent of side-effects and is well tolerated by patients, including those of older age groups.

Topics: Adrenocorticotropic Hormone; Adult; Age Factors; Aged; Cerebrovascular Disorders; Disease Progression; Electroencephalography; Female; Follow-Up Studies; Fundus Oculi; Geriatric Assessment; Humans; Hypertension; Intracranial Arteriosclerosis; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Nootropic Agents; Peptide Fragments; Personality Inventory; Risk Factors; Stroke; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Transcranial